Swedish Orphan Biovitrum AB's next confirmed earnings release is scheduled for February 4, 2027.
| Earnings Date | 2/4/2027 |
As of September 30, 2026, Swedish Orphan Biovitrum AB has 348.00M shares outstanding.
| Shares Outstanding | 348.00M |
As of September 30, 2026, Swedish Orphan Biovitrum AB maintains a current ratio of 0.99, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.99 |
| Quick Ratio | 0.05 |
| Debt / Equity | 35.56 |
| Debt / EBITDA | 1.27 |
These figures cover the twelve months ended September 30, 2026. The company generates approximately 30.58M in revenue per employee across its workforce of 1,888.00, a quick read on workforce productivity versus industry peers.
| Revenue Per Employee | 30.58M |
| Employee Count | 1,888.00 |
Over the twelve months ended September 30, 2026, Swedish Orphan Biovitrum AB recorded 3.03B in income tax expense. That works out to an effective tax rate of 20.19, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 14.99B, leaving 11.96B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 3.03B |
| Effective Tax Rate | 20.19 |
As of the close on November 12, 2026, Swedish Orphan Biovitrum AB's stock has gained approximately 182.20% over the past 52 weeks.
| 52-Week Price Change | 182.20% |
Over the twelve months ended September 30, 2026, Swedish Orphan Biovitrum AB generated 57.73B in revenue and converted that into 11.96B in net income, yielding earnings per share of 34.20. EBITDA reached 22.90B, while operating income came in at 17.19B.
| Revenue | 57.73B |
| Gross Profit | 44.73B |
| Operating Income | 17.19B |
| Pretax Income | 14.99B |
| Net Income | 11.96B |
| EBITDA | 22.90B |
| EBIT | 16.39B |
| Earnings Per Share (EPS) | 34.20 |
As of September 30, 2026, Swedish Orphan Biovitrum AB holds 1.81B in cash and equivalents against 29.17B in total debt, resulting in a net debt position of 26.69B. Total book value stands at 82.01B, with working capital of -303.36M providing operational flexibility.
| Cash & Cash Equivalents | 1.81B |
| Total Debt | 29.17B |
| Net Debt | 26.69B |
| Equity (Book Value) | 82.01B |
| Book Value Per Share | 235.66 |
| Working Capital | -303.36M |
Swedish Orphan Biovitrum AB produced 14.25B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -2.50B in capital expenditures, free cash flow totaled 11.75B - equivalent to 33.92 per share.
| Operating Cash Flow | 14.25B |
| Capital Expenditures | -2.50B |
| Free Cash Flow | 11.75B |
| FCF Per Share | 33.92 |
Over the twelve months ended September 30, 2026, Swedish Orphan Biovitrum AB posted a gross margin of 77.48, reflecting its pricing power and cost economics. The operating margin of 29.78 and net profit margin of 20.73 provide insight into operational efficiency.
| Gross Margin | 77.48 |
| Operating Margin | 29.78 |
| Pretax Margin | 25.97 |
| Profit Margin | 20.73 |
| EBITDA Margin | 39.67 |
Swedish Orphan Biovitrum AB's most recent stock split took place on August 28, 2023.
| Last Split Date | 8/28/2023 |
Already premium?